-->

Is Long-Term PPI Use Safe? What the Research Shows

Teal capsules and scattered red pills on a gray tabletop

For most people who have a clear reason to take one, a proton pump inhibitor (PPI) at the lowest dose that works is reasonably safe, even for years. The largest randomized trial of long-term PPI use, which followed more than 17,000 people for about three years, found no increase in kidney disease, fractures, dementia, pneumonia or heart problems, only a small rise in gut infections. The bigger risk is staying on a PPI you no longer need, because large observational studies do link long-term use to kidney disease, hip fractures, low vitamin B12, C. difficile infection and, after H. pylori treatment, stomach cancer.

This guide sorts those risks by how strong the evidence is, explains who benefits from staying on a PPI, and covers how to use less with your doctor's help.

The short answer, by situation

Your situation What the evidence suggests
Erosive esophagitis, peptic stricture or Barrett's esophagus Long-term PPI use is usually recommended. The benefit outweighs the possible risks.
Taking NSAIDs and at high risk of ulcer bleeding A PPI is usually recommended for as long as the NSAID continues.
Uncomplicated heartburn that got better on a short course Guidelines say to try reducing or stopping, with your doctor.
Not sure why you started Ask your doctor to review it. Many long-term prescriptions are never rechecked.
Taking twice a day Ask whether once a day would be enough.

That table follows the American Gastroenterological Association (AGA) best practice advice from 2017 and its 2022 update on deprescribing. Both say the deciding question is whether you still have a reason to take the drug.

What counts as "long-term"?

Over-the-counter PPI packages are labeled for a 14-day course, up to three times a year. Prescription courses for reflux usually run 4 to 8 weeks. Most of the studies below looked at people taking a PPI for at least a year, and several found that risk rose with each additional year or with higher doses.

Common PPIs include omeprazole (Prilosec), esomeprazole (Nexium), lansoprazole (Prevacid), pantoprazole (Protonix), rabeprazole (Aciphex) and dexlansoprazole (Dexilant). They all work the same way, by switching off the acid pumps in the stomach lining, and none has been shown to be safer than the others for long-term use.

Why the research seems to disagree

Most headlines about PPI dangers come from observational studies. Researchers compare people who happened to take PPIs with people who did not. That design can show a link but cannot prove the drug caused it. People who take PPIs for years are, on average, older, sicker and on more medications, and those differences are hard to adjust away.

A randomized trial avoids that problem by assigning the drug at random. The COMPASS trial did this at scale: people with heart or artery disease took pantoprazole 40 mg or a placebo for a median of three years. Pantoprazole did not raise rates of pneumonia, fractures, chronic kidney disease, dementia, diabetes, cancer, heart events or death. Enteric (gut) infections were slightly more common, 1.4% versus 1.0%. C. difficile cases were too few to draw a firm conclusion.

COMPASS has limits too. Its participants were mostly older adults with heart disease, three years is shorter than many people take PPIs, and it was not designed to catch rare outcomes such as stomach cancer. The fair reading is that some feared risks are probably smaller than early studies suggested, while others still deserve attention.

Long-term PPI side effects, ranked by strength of evidence

Possible risk Key finding How solid?
Gut infections Higher in the COMPASS randomized trial (1.4% vs 1.0%); C. difficile odds about 1.7 times higher in a meta-analysis Strongest
Low vitamin B12 2+ years of PPI use linked to 65% higher odds of deficiency Moderate (large observational study, clear mechanism)
Hip fracture More than 1 year of use linked to 44% higher odds; higher with high doses Moderate, but not confirmed in COMPASS
Chronic kidney disease 20% to 50% higher risk in large cohorts Mixed; not confirmed in COMPASS
Stomach cancer after H. pylori treatment 2.44 times higher risk, rising with years of use One large population study; specific group
Dementia, heart attack, pneumonia Linked in some observational studies Weak; COMPASS found no increase

Gut infections and C. difficile

Stomach acid kills many of the bacteria that arrive with food. With less acid, more of them survive the trip to the intestines. This is the one risk that showed up in a randomized trial, which makes it the most believable. A 2012 meta-analysis of 42 observational studies covering about 313,000 people found PPI users had 1.74 times the odds of C. difficile infection, and 2.51 times the odds of a repeat infection. Taking antibiotics at the same time raised the risk further.

Vitamin B12

Acid helps release vitamin B12 from the protein in food. In a Kaiser Permanente study of about 26,000 people with B12 deficiency and 184,000 without, two or more years of PPI use was linked to 65% higher odds of deficiency. Higher daily doses carried higher odds. Low B12 develops slowly and can show up as tiredness, numbness or tingling, or memory problems, which is why it is easy to miss.

Fractures

A 2006 study of more than 13,000 people over 50 who broke a hip, compared with 135,000 who did not, found that more than a year of PPI use was linked to 44% higher odds of hip fracture. The odds rose with each year of use, and high-dose long-term use was linked to more than double the odds. Reduced calcium absorption is the leading explanation. COMPASS did not find more fractures, so this risk may be smaller in practice, but it matters most for people who already have thin bones.

Kidney disease

Two large studies drive most of the concern. In the ARIC cohort of 10,482 adults, PPI users had a 50% higher risk of chronic kidney disease after adjustment, and a second cohort of nearly 249,000 patients showed a 24% higher risk. Twice-daily dosing carried more risk than once-daily. A US veterans study of about 125,600 PPI users, compared with 18,400 people on H2 blockers, found a 26% higher risk of chronic kidney disease and a 30% higher risk of end-stage kidney disease or a large drop in kidney function. Only about 45% of the extra kidney risk ran through a recognized episode of acute kidney injury, so in many cases the decline was gradual and gave no obvious warning.

COMPASS did not find more kidney disease with pantoprazole over three years. The kidney link remains a reasonable concern for people on high doses for many years, and a good reason not to stay on a PPI without a reason. Our article on PPIs and kidney damage covers this in more depth.

Stomach cancer after H. pylori treatment

A Hong Kong study followed 63,397 people for a median of 7.6 years after they had been treated for H. pylori, the bacterium linked to ulcers and stomach cancer. Long-term PPI use was linked to 2.44 times the risk of stomach cancer, and the risk rose with longer use. H2 blockers, a milder type of acid reducer, showed no such link. Stomach cancer was still rare: 153 cases among more than 63,000 people. The finding applies to people who have had H. pylori, and it is one more reason to review long-term use rather than a reason to panic.

Dementia, heart disease and pneumonia

Some observational studies have linked PPIs to dementia, heart attack and pneumonia. These links have been inconsistent across studies, and the COMPASS trial found no increase in any of them. Based on current evidence, they are not strong reasons by themselves to stop a PPI you need.

What experts recommend

The AGA's position is practical. In 2017 it advised that anyone on a long-term PPI should have the dose reviewed periodically so they take the lowest effective dose, and that people with uncomplicated reflux who did well on a short course should try to reduce or stop. It did not recommend routine bone density scans, kidney tests, or magnesium or B12 checks just because someone takes a PPI, and it did not recommend extra calcium, B12 or magnesium supplements as routine. Your doctor may still check these if you have symptoms or other risk factors.

The 2022 AGA update added three useful points:

  • Every long-term prescription should have a documented reason, reviewed regularly.
  • The decision to stop should be based on whether you still need the drug, not on fear of side effects alone.
  • People who stop should be told that a short-lived return of symptoms from rebound acid is common.

Do not stop a prescribed PPI on your own. If you have Barrett's esophagus, severe esophagitis, a stricture, a history of bleeding ulcers, or take blood thinners or NSAIDs, the reasons to stay on it may be strong. Your doctor can tell you which group you are in.

Rebound acid: why PPIs are hard to stop

When acid is suppressed for weeks, the stomach responds by raising gastrin, the hormone that drives acid production. When the drug stops, acid output can briefly overshoot. In a 2009 trial, 120 healthy volunteers with no reflux took esomeprazole 40 mg or placebo for 8 weeks. In the four weeks after stopping, 44% of the esomeprazole group had acid-related symptoms such as heartburn or regurgitation, compared with 15% of the placebo group.

Those symptoms are temporary, but they often feel like proof that the PPI is still needed. Knowing they are likely, and planning for them with your doctor, makes reducing the dose more realistic. Our guide to stopping PPIs and rebound acid walks through how a step-down usually works.

Ways to need less acid suppression

If you and your doctor decide to reduce or stop, these options can help with symptoms along the way:

  • Weight loss and raising the head of the bed. A 2006 review of lifestyle measures found these two had the best evidence for improving reflux. Lying on the left side also helped. Cutting specific foods, alcohol or smoking did not show clear benefit in the studies reviewed, though some people find individual triggers worth avoiding.
  • Alginates (such as Gaviscon Advance). These form a foam raft on top of stomach contents. A 2017 meta-analysis of 14 trials with 2,095 people found they worked better than placebo or antacids for reflux symptoms.
  • H2 blockers (such as famotidine). Milder acid reducers that doctors often use during a step-down or for occasional symptoms.
  • D-limonene, a compound from orange peel. A 2007 review described two small, unpublished trials in which most people taking 1,000 mg of d-limonene reported heartburn relief within two weeks. That evidence is limited, and larger published trials are still needed. Our complete guide to d-limonene covers what is and is not known.

For a side-by-side look at the options, see our guides to alternatives to PPIs and d-limonene vs PPIs. Orange Burps is a d-limonene supplement that may help support digestive comfort.

Questions to ask your doctor

  • Why did I start this PPI, and does that reason still apply?
  • Have I ever had an endoscopy that showed erosive esophagitis or Barrett's esophagus?
  • Could I take a lower dose, or once a day instead of twice?
  • Given my age, bones and kidneys, should anything be checked?
  • If we reduce the dose, what should I use for rebound symptoms?

See a doctor promptly if you have trouble swallowing, unexplained weight loss, vomiting, black stools or anemia. If you have chest pain, call 911, since heart problems can feel like heartburn.

Frequently asked questions

Is it safe to take a PPI every day for years?

It can be, if you have a condition that needs it and take the lowest dose that works. The largest randomized trial found no increase in most feared problems over three years, apart from a small rise in gut infections. Observational studies link long-term use to kidney disease, fractures and low B12, so a regular review with your doctor makes sense.

What are the most common long-term PPI side effects?

The best-supported are gut infections, including C. difficile, and low vitamin B12. Links to hip fractures and chronic kidney disease come from large observational studies but were not confirmed in the COMPASS trial.

Is one PPI safer than another for long-term use?

No PPI has been shown to be safer than the others over the long term. They share the same mechanism. Some differ in drug interactions, which your pharmacist can check.

Should I stop my PPI because of these risks?

Not on your own. Experts recommend stopping when there is no longer a reason to take it, not because of side effect fears alone. Talk to your doctor about whether you still need it and how to reduce it.

References

  1. Moayyedi P, Eikelboom JW, Bosch J, et al. (2019). Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin. Gastroenterology.
  2. Freedberg DE, Kim LS, Yang YX (2017). The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association. Gastroenterology.
  3. Targownik LE, Fisher DA, Saini SD (2022). AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors: Expert Review. Gastroenterology.
  4. Kwok CS, Arthur AK, Anibueze CI, et al. (2012). Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. American Journal of Gastroenterology.
  5. Lam JR, Schneider JL, Zhao W, Corley DA (2013). Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA.
  6. Yang YX, Lewis JD, Epstein S, Metz DC (2006). Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA.
  7. Lazarus B, Chen Y, Wilson FP, et al. (2016). Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease. JAMA Internal Medicine.
  8. Xie Y, Bowe B, Li T, et al. (2017). Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney International.
  9. Cheung KS, Chan EW, Wong AYS, et al. (2018). Long-term proton pump inhibitors and risk of gastric cancer development after treatment for Helicobacter pylori: a population-based study. Gut.
  10. Reimer C, Søndergaard B, Hilsted L, Bytzer P (2009). Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. Gastroenterology.
  11. Kaltenbach T, Crockett S, Gerson LB (2006). Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Archives of Internal Medicine.
  12. Leiman DA, Riff BP, Morgan S, et al. (2017). Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Diseases of the Esophagus.
  13. Sun J (2007). D-Limonene: safety and clinical applications. Alternative Medicine Review.

This article is for general information and is not medical advice. Talk to your doctor before starting, changing or stopping any medication.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

Get a natural treatment for heartburn and acid reflux!

top